泓博医药
(301230)
| 流通市值：20.73亿 | | | 总市值：37.58亿 |
| 流通股本：5937.17万 | | | 总股本：1.08亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 130,725,745.26 | 489,717,074.89 | 367,212,523.37 | 237,655,059.97 |
| 营业收入 | 130,725,745.26 | 489,717,074.89 | 367,212,523.37 | 237,655,059.97 |
| 二、营业总成本 | 135,325,810.41 | 450,092,838.01 | 319,387,817.06 | 200,328,331.16 |
| 营业成本 | 103,778,044.13 | 338,514,627.37 | 240,119,484.14 | 149,336,941.34 |
| 税金及附加 | 521,749.41 | 1,241,753.94 | 915,160.49 | 555,131.18 |
| 销售费用 | 3,184,050.17 | 12,896,930.53 | 8,888,306.9 | 5,522,548.53 |
| 管理费用 | 16,112,686.45 | 60,688,102.74 | 43,886,738.79 | 28,819,361.45 |
| 研发费用 | 11,274,826.18 | 37,336,023.31 | 28,719,012.45 | 19,284,150.46 |
| 财务费用 | 454,454.07 | -584,599.88 | -3,140,885.71 | -3,189,801.8 |
| 其中:利息费用 | 2,410,254.65 | 5,462,237.16 | 2,940,547.93 | 2,030,341.21 |
| 其中:利息收入 | 724,215.75 | 5,526,616.74 | 4,163,429.14 | 3,518,749.04 |
| 加:公允价值变动收益 | 1,194,880.73 | 5,580,646.47 | 2,357,183.57 | -2,986,215.19 |
| 加:投资收益 | 1,938,566.65 | 628,463.41 | 726,006.94 | 3,015,155.93 |
| 资产处置收益 | - | 5,799.54 | 5,799.54 | 3,020.49 |
| 资产减值损失(新) | 3,258,818.23 | -12,093,289.1 | -2,407,037.97 | -2,009,778.3 |
| 信用减值损失(新) | -795,773.29 | -273,136.2 | -151,336.61 | 1,005,917.8 |
| 其他收益 | 768,289.85 | 3,971,599.62 | 1,139,587.97 | 416,428.87 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,764,717.02 | 37,444,320.62 | 49,494,909.75 | 36,771,258.41 |
| 加:营业外收入 | 121,610 | 26,279.31 | 6,750.22 | 6,750.02 |
| 减:营业外支出 | 28,449.52 | 707,820.16 | 502,018.64 | 279,580.57 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,857,877.5 | 36,762,779.77 | 48,999,641.33 | 36,498,427.86 |
| 减:所得税费用 | -1,809,783.06 | -856,469.32 | 3,065,623.61 | 3,610,235.1 |
| 六、净利润 | 3,667,660.56 | 37,619,249.09 | 45,934,017.72 | 32,888,192.76 |
| 持续经营净利润 | 3,667,660.56 | 37,619,249.09 | 45,934,017.72 | 32,888,192.76 |
| 归属于母公司股东的净利润 | 3,667,660.56 | 37,619,249.09 | 45,934,017.72 | 32,888,192.76 |
| (一)基本每股收益 | 0.03 | 0.35 | 0.43 | 0.31 |
| (二)稀释每股收益 | 0.03 | 0.35 | 0.43 | 0.31 |
| 八、其他综合收益 | - | 82,460.86 | 69,910.26 | 82,460.86 |
| 归属于母公司股东的其他综合收益 | - | 82,460.86 | 69,910.26 | 82,460.86 |
| 九、综合收益总额 | 3,667,660.56 | 37,701,709.95 | 46,003,927.98 | 32,970,653.62 |
| 归属于母公司股东的综合收益总额 | 3,667,660.56 | 37,701,709.95 | 46,003,927.98 | 32,970,653.62 |
| 公告日期 | 2024-04-26 | 2024-04-24 | 2023-10-26 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |